KR102961371B1 - Dna-의존적 단백질 키나제 억제제 - Google Patents
Dna-의존적 단백질 키나제 억제제Info
- Publication number
- KR102961371B1 KR102961371B1 KR1020217039462A KR20217039462A KR102961371B1 KR 102961371 B1 KR102961371 B1 KR 102961371B1 KR 1020217039462 A KR1020217039462 A KR 1020217039462A KR 20217039462 A KR20217039462 A KR 20217039462A KR 102961371 B1 KR102961371 B1 KR 102961371B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- mmol
- pyrimidine
- pyrazolo
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/088573 | 2019-05-27 | ||
| CN2019088573 | 2019-05-27 | ||
| PCT/CN2020/092351 WO2020238900A1 (en) | 2019-05-27 | 2020-05-26 | Dna-dependent protein kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220027062A KR20220027062A (ko) | 2022-03-07 |
| KR102961371B1 true KR102961371B1 (ko) | 2026-05-06 |
Family
ID=73551904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217039462A Active KR102961371B1 (ko) | 2019-05-27 | 2020-05-26 | Dna-의존적 단백질 키나제 억제제 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12630565B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3976624A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7696834B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102961371B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113924305A (cg-RX-API-DMAC7.html) |
| AR (1) | AR119018A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020281332B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021023824A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3137598A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014455A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI899080B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020238900A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021213460A1 (zh) * | 2020-04-23 | 2021-10-28 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| CN114634521A (zh) * | 2020-12-15 | 2022-06-17 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656486B (zh) * | 2020-12-22 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| WO2022148354A1 (zh) * | 2021-01-05 | 2022-07-14 | 山东轩竹医药科技有限公司 | 多环类激酶抑制剂 |
| WO2022177302A1 (ko) * | 2021-02-17 | 2022-08-25 | 보령제약 주식회사 | Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ck12抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CA3245866A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
| CN117003754B (zh) * | 2022-04-28 | 2025-07-25 | 腾讯科技(深圳)有限公司 | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 |
| US20230399313A1 (en) * | 2022-06-10 | 2023-12-14 | Advenchen Pharmaceuticals, LLC | Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers |
| CN115322209B (zh) * | 2022-07-19 | 2023-06-20 | 湖北理工学院 | 作为dna-pk抑制剂的三并环化合物 |
| CN116239610B (zh) * | 2023-02-23 | 2024-01-16 | 遵义医科大学珠海校区 | 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用 |
| EP4720069A4 (en) * | 2023-07-21 | 2026-07-22 | Wei Zhong | Substituted 2-AMINO-9-(3,3-DIFLOOROPIPERIDIN-4-YL)-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AND THEIR USE IN CANCER TREATMENT |
| WO2025179188A1 (en) * | 2024-02-22 | 2025-08-28 | Juno Therapeutics, Inc. | Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| WO2006074984A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
| WO2006074985A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| JP2006241089A (ja) * | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
| JP2008530191A (ja) * | 2005-02-16 | 2008-08-07 | アストラゼネカ アクチボラグ | 化学化合物 |
| WO2011156698A2 (en) * | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| JP2016510045A (ja) * | 2013-03-05 | 2016-04-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EA022120B1 (ru) | 2009-10-20 | 2015-11-30 | Целльзом Лимитид | Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak |
| WO2011106168A1 (en) * | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| US20130035336A1 (en) * | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| WO2011134831A1 (en) | 2010-04-30 | 2011-11-03 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
| JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| KR20140063700A (ko) | 2011-09-20 | 2014-05-27 | 셀좀 리미티드 | 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체 |
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) * | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| WO2015115673A1 (en) * | 2014-01-31 | 2015-08-06 | Ono Pharmaceutical Co., Ltd. | Fused imidazole compounds |
| DK3558997T3 (da) * | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
| JP7230053B2 (ja) | 2017-12-05 | 2023-02-28 | オスコテック インコーポレイテッド | Lrrk2阻害剤としてのピロロ(ピラゾロ)ピリミジン誘導体 |
| TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| CN110885331B (zh) | 2018-09-11 | 2021-07-09 | 中国药科大学 | 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK激酶抑制剂的制备与应用 |
-
2020
- 2020-05-25 TW TW109117346A patent/TWI899080B/zh active
- 2020-05-26 US US17/614,384 patent/US12630565B2/en active Active
- 2020-05-26 EP EP20815132.4A patent/EP3976624A4/en active Pending
- 2020-05-26 CA CA3137598A patent/CA3137598A1/en active Pending
- 2020-05-26 MX MX2021014455A patent/MX2021014455A/es unknown
- 2020-05-26 JP JP2021570368A patent/JP7696834B2/ja active Active
- 2020-05-26 WO PCT/CN2020/092351 patent/WO2020238900A1/en not_active Ceased
- 2020-05-26 BR BR112021023824A patent/BR112021023824A8/pt unknown
- 2020-05-26 CN CN202080039438.4A patent/CN113924305A/zh active Pending
- 2020-05-26 AU AU2020281332A patent/AU2020281332B2/en active Active
- 2020-05-26 KR KR1020217039462A patent/KR102961371B1/ko active Active
- 2020-05-27 AR ARP200101492A patent/AR119018A1/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| WO2006074984A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as cell cycle kinase inhibitors |
| WO2006074985A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| JP2008530191A (ja) * | 2005-02-16 | 2008-08-07 | アストラゼネカ アクチボラグ | 化学化合物 |
| JP2006241089A (ja) * | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
| WO2011156698A2 (en) * | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| JP2016510045A (ja) * | 2013-03-05 | 2016-04-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020281332A8 (en) | 2021-11-18 |
| JP2022534261A (ja) | 2022-07-28 |
| BR112021023824A8 (pt) | 2023-02-28 |
| AU2020281332A1 (en) | 2021-11-04 |
| US12630565B2 (en) | 2026-05-19 |
| AU2020281332B2 (en) | 2026-04-02 |
| EP3976624A4 (en) | 2023-06-14 |
| TW202110849A (zh) | 2021-03-16 |
| US20220242884A1 (en) | 2022-08-04 |
| BR112021023824A2 (pt) | 2022-01-04 |
| KR20220027062A (ko) | 2022-03-07 |
| CN113924305A (zh) | 2022-01-11 |
| CA3137598A1 (en) | 2020-12-03 |
| JP7696834B2 (ja) | 2025-06-23 |
| EP3976624A1 (en) | 2022-04-06 |
| TWI899080B (zh) | 2025-10-01 |
| WO2020238900A1 (en) | 2020-12-03 |
| AR119018A1 (es) | 2021-11-17 |
| MX2021014455A (es) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI899080B (zh) | Dna依賴性蛋白激酶抑制劑 | |
| ES2933980T3 (es) | Degradadores selectivos de receptores de estrógenos | |
| ES2907759T3 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]isoquinolina útiles en el tratamiento del cáncer | |
| EP3724190B1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| CN114394966B (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| EP3237423B1 (en) | Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors | |
| EP2931722B1 (en) | Substituted 1h-pyrrolo [2,3-b]pyridine and 1h-pyrazolo [3, 4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors | |
| EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
| JP5581390B2 (ja) | Akt阻害剤 | |
| JP2021522281A (ja) | がんの治療のためのkras g12c阻害剤 | |
| TWI626241B (zh) | 3環性吡咯並吡啶化合物及jak阻斷劑 | |
| KR20160145796A (ko) | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 | |
| AU2016243939A1 (en) | Heterocyclic compounds as LSD1 inhibitors | |
| TWI744866B (zh) | 用於治療pah之抗增生藥劑 | |
| CA3119882A1 (en) | Heterocyclic spiro-compounds as am2 receptor inhibitors | |
| RU2835434C2 (ru) | Ингибитор ДНК-зависимой протеинкиназы | |
| WO2023101895A1 (en) | Fused pyrazole urea analogs as glucosylceramide synthase inhibitors | |
| CA3212212A1 (en) | Cyclic compounds and methods of using same | |
| HK40060710A (en) | Dna-dependent protein kinase inhibitor | |
| WO2026041008A1 (en) | Maleic acid derivatives and uses thereof | |
| CN117940425A (zh) | Her2突变抑制剂 | |
| EA040517B1 (ru) | Селективные супрессоры рецептора эстрогена | |
| HK40033314B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| HK40033314A (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| HK1237340B (en) | Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |